C-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

Cancer Cell

Volumn 19, Issue 5, 2011, Pages 652-663

  Blasco, Rafael B ^a   Francoz, Sarah ^a   Santamaría, David ^a   Cañamero, Marta ^a   Dubus, Pierre ^b   Charron, Jean ^c   Baccarini, Manuela ^d   Barbacid, Mariano ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; RAF PROTEIN;

ABLATION THERAPY; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HOMEOSTASIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

MUS;

EID: 79955980366     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.04.002     Document Type: Article

References (50)

1. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
2. Belanger L.F., Roy S., Tremblay M., Brott B., Steff A.M., Mourad W., Hugo P., Erikson R., Charron J. Mek2 is dispensable for mouse growth and development. Mol. Cell. Biol. 2003, 23:4778-4787.
3. Bissonauth V., Roy S., Gravel M., Guillemette S., Charron J. Requirement for Mak2k1 (Mek1) in extra-embryonic ectoderm placentogenesis. Development 2006, 133:3429-3440.
4. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
5. Camonis J.H., White M.A. Ral GTPases: corrupting the exocyst in cancer cells. Trends Cell Biol. 2005, 15:327-332.
6. Catalanotti F., Reyes G., Jesenberger V., Galabova-Kovacs G., de Matos Simoes R., Carugo O., Baccarini M. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat. Struct. Mol. Biol. 2009, 16:294-303.
7. Chen A.P., Ohno M., Giese K.P., Kühn R., Chen R.L., Silva A.J. Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory. J. Neurosci. Res. 2006, 83:28-38.
8. Cully M., You H., Levine A.J., Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6:184-192.
9. De Roock W., Jonker D.J., Di Nicolantonio F., Sartore-Bianchi A., Tu D., Siena S., Lamba S., Arena S., Frattini M., Piessevaux H., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304:1812-1820.
10. Dumaz N., Hayward R., Martin J., Ogilvie L., Hedley D., Curtin J.A., Bastian B.C., Springer C., Marais R. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006, 66:9483-9491.
11. Ehrenreiter K., Kern F., Velamoor V., Meissl K., Galabova-Kovacs G., Sibilia M., Baccarini M. Raf-1 addiction in ras-induced skin carcinogenesis. Cancer Cell 2009, 16:149-160.
12. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
13. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
14. Fischer A.M., Katayama C.D., Pagès G., Pouysségur J., Hedrick S.M. The role of erk1 and erk2 in multiple stages of T cell development. Immunity 2005, 23:431-443.
15. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
16. Galabova-Kovacs G., Kolbus A., Matzen D., Meissl K., Piazzolla D., Rubiolo C., Steinitz K., Baccarini M. ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle 2006, 5:1514-1518.
17. Giroux S., Tremblay M., Bernard D., Cardin-Girard J.F., Aubry S., Larouche L., Rousseau S., Huot J., Landry J., Jeannotte L., et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 1999, 9:369-372.
18. Guerra C., Mijimolle N., Dhawahir A., Dubus P., Barradas M., Serrano M., Campuzano V., Barbacid M. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003, 4:111-120.
19. Gupta S., Ramjaun A.R., Haiko P., Wang Y., Warne P.H., Nicke B., Nye E., Stamp G., Alitalo K., Downward J. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007, 129:957-968.
20. Haigis K.M., Kendall K.R., Wang Y., Cheung A., Haigis M.C., Glickman J.N., Niwa-Kawakita M., Sweet-Cordero A., Sebolt-Leopold J., Shannon K.M., et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 2008, 40:600-608.
21. Hainsworth J.D., Cebotaru C.L., Kanarev V., Ciuleanu T.E., Damyanov D., Stella P., Ganchev H., Pover G., Morris C., Tzekova V. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J. Thorac. Oncol. 2010, 5:1630-1636.
22. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J., Stokoe D., Gloor S.L., Vigers G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
23. Haura E.B., Ricart A.D., Larson T.G., Stella P.J., Bazhenova L., Miller V.A., Cohen R.B., Eisenberg P.D., Selaru P., Wilner K.D., et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2010, 16:2450-2457.
24. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
25. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005, 65:10280-10288.
26. Jesenberger V., Procyk K.J., Ruth J., Schreiber M., Theussl H.C., Wagner E.F., Baccarini M. Protective role of Raf-1 in Salmonella-induced macrophage apoptosis. J. Exp. Med. 2001, 193:353-364.
27. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410:1111-1116.
28. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9:517-531.
29. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., Wong K.K., Elledge S.J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
30. Malliri A., Collard J.G. Role of Rho-family proteins in cell adhesion and cancer. Curr. Opin. Cell Biol. 2003, 15:583-589.
31. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 2003, 3:459-465.
32. Marshall C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Dev. 1994, 4:82-89.
33. Matallanas D., Romano D., Yee K., Meissl K., Kucerova L., Piazzolla D., Baccarini M., Vass J.K., Kolch W., O'neill E. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol. Cell 2007, 27:962-975.
34. Meylan E., Dooley A.L., Feldser D.M., Shen L., Turk E., Ouyang C., Jacks T. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462:104-107.
35. Mikula M., Schreiber M., Husak Z., Kucerova L., Rüth J., Wieser R., Zatloukal K., Beug H., Wagner E.F., Baccarini M. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J. 2001, 20:1952-1962.
36. Niault T., Sobczak I., Meissl K., Weitsman G., Piazzolla D., Maurer G., Kern F., Ehrenreiter K., Hamerl M., Moarefi I., et al. From autoinhibition to inhibition in trans: the Raf-1 regulatory domain inhibits Rok-alpha kinase activity. J. Cell Biol. 2009, 187:335-342.
37. Pagès G., Guérin S., Grall D., Bonino F., Smith A., Anjuere F., Auberger P., Pouysségur J. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999, 286:1374-1377.
38. Piazzolla D., Meissl K., Kucerova L., Rubiolo C., Baccarini M. Raf-1 sets the threshold of Fas sensitivity by modulating Rok-alpha signaling. J. Cell Biol. 2005, 171:1013-1022.
39. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
40. Puyol M., Martín A., Dubus P., Mulero F., Pizcueta P., Khan G., Guerra C., Santamaría D., Barbacid M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18:63-73.
41. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., Hamid O., Varterasian M., Asbury P., Kaldjian E.P., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004, 22:4456-4462.
42. Scholl F.A., Dumesic P.A., Barragan D.I., Harada K., Charron J., Khavari P.A. Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. Cancer Res. 2009, 69:3772-3778.
43. Simpson A.J., Wallace W.A., Marsden M.E., Govan J.R., Porteous D.J., Haslett C., Sallenave J.M. Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J. Immunol. 2001, 167:1778-1786.
44. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with " K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
45. Takezawa K., Okamoto I., Yonesaka K., Hatashita E., Yamada Y., Fukuoka M., Nakagawa K. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res. 2009, 69:6515-6521.
46. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 2008, 105:3041-3046.
47. Tuveson D.A., Shaw A.T., Willis N.A., Silver D.P., Jackson E.L., Chang S., Mercer K.L., Grochow R., Hock H., Crowley D., et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004, 5:375-387.
48. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X., Gimotty P.A., Kee D., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695.
49. Voice J.K., Klemke R.L., Le A., Jackson J.H. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J. Biol. Chem. 1999, 274:17164-17170.
50. Yamaguchi O., Watanabe T., Nishida K., Kashiwase K., Higuchi Y., Takeda T., Hikoso S., Hirotani S., Asahi M., Taniike M., et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J. Clin. Invest. 2004, 114:937-943.